Abstract
Treating to target is an established concept in a number of long-term conditions, aiming to improve outcomes and prevent disease progression. In rheumatoid arthritis (RA), treatment targets are controlling the signs and symptoms of significant inflammatory disease activity, with the ultimate goal of remission from disease. This article briefly outlines the disease process of RA and examines the role of disease-modifying anti-rheumatic drugs, steroids and biologic agents in controlling disease activity. The rational use of analgesia and non-steroidal anti-inflammatory drugs is highlighted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
